title: Luminal (Her2 negative) prognostic index and survival of breast cancer patients.
abstract: OBJECTIVE
  The group of luminal (Her2 negative) is distinguished from other subtypes of breast cancer. We aimed to produce a prognostic index specific for luminal (Her2 negative) subtype breast cancer that could assist clinical treatment.
  
  
  METHODS
  The test set comprised 406 consecutive luminal (Her2 negative) breast cancer patients. The relationship of 11 clinicopathologic factors including survivin with the 5-year disease-free survival was analyzed.
  
  
  RESULTS
  In univariate analysis, TNM stage, surgery, tumor size, lymph node involvement, and survivin expression were prognostic factors. In multivariate analysis, tumor size [HR (95% CI): 1.98 (1.12-3.49), p=0.019], the number of lymph node metastasis [HR (95% CI): 1.75 (1.33-2.29), p<0.0001] and the expression of progesterone receptor [HR (95% CI): 0.58 (0.36-0.95), p=0.029] can independently predict prognosis. Prognostic index (PI) was calculated as 0.68×tumor size+0.56×the number of lymph node metastasis-0.54×PR. According to the PI, patients were categorized into three groups: low, middle, and high risk group with the 5-year disease-free survival rates of 91.91%, 84.97% and 70.47%, respectively (P<0.001). In the validation set, the luminal prognostic index (LPI) remained significant.
  
  
  CONCLUSIONS
  The LPI may be a useful tool for evaluating the outcome of patients with luminal (Her-2 negative) breast cancer.
authors.affiliation: Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.
authors.forename: Xuesong
authors.initials: X
authors.lastname: Chen
authors.affiliation: Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.
authors.forename: Yingying
authors.initials: Y
authors.lastname: Cong
authors.affiliation: Department of Oncology, The Affiliated Hospital of Jining Medical College, Jining, Shandong Province, China.
authors.forename: Lihua
authors.initials: L
authors.lastname: Pan
authors.affiliation: Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Jiang
authors.affiliation: Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.
authors.forename: Qingwei
authors.initials: Q
authors.lastname: Meng
authors.affiliation: Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.
authors.forename: Lichun
authors.initials: L
authors.lastname: Sun
authors.affiliation: Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Pang
authors.affiliation: Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China.
authors.forename: Yanbin
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Pharmacy Building, 7 Greenhouse Road, Kingston, RI 02881, USA. Electronic address: xiaoqun_dong@mail.uri.edu.
authors.forename: Xiaoqun
authors.initials: X
authors.lastname: Dong
authors.affiliation: Department of Internal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang Province, China. Electronic address: caiwenxin76@163.com.
authors.forename: Li
authors.initials: L
authors.lastname: Cai
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000201:enzymology* / Q000401:mortality* / Q000473:pathology; D002681:China / Q000453:epidemiology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D010634:Phenobarbital / Q000737:chemistry; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis*; D016019:Survival Analysis; D055815:Young Adult
chemical_list: D010634:Phenobarbital; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human
keywords: Breast cancer; Luminal; Progesterone receptor; Prognostic index; Survivin